R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151
Srdan Verstovsek,Olga Pozdnyakova,Robert P. Hasserjian,Mohamed E. Salama,Ruben A. Mesa,Lynda Foltz,Vikas Gupta,John Mascarenhas,Ellen K. Ritchie,Ronald Hoffman,Richard T. Silver,Marina Kremyanskaya,Elizabeth Trehu,Hagop M. Kantarjian,Jason Gotlib +14 more
TL;DR: Although most of the patients have apparently the diagnosis of PMF, it took almost 10 months to be done and an expressive number of medical reports do not show a complete history, while 2030% of them don’t have all the laboratory tools for a precise diagnosis.
Journal ArticleDOI
Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia.
TL;DR: The long-term treatment experience with the purine nucleoside analog 2-chlorodeoxyadenosine (2-CdA) in myelofibrosis with myeloid metaplasia has improved, with a >50% reduction in palpable hepatomegaly.
Journal ArticleDOI
Ps1459 fedratinib in patients with myeloproliferative neoplasm (mpn)-associated myelofibrosis (mf) previously treated with ruxolitinib (rux): a reanalysis of the phase 2 jakarta-2 study
C. Harrison,N. Schaap,Alessandro M. Vannucchi,J.-J. Kiladjian,E. Jourdan,Richard T. Silver,Harry C. Schouten,Francesco Passamonti,Sonja Zweegman,M. Talpaz,Srdan Verstovsek,T. Gerike,S. Rose,M. Li,C. Brownstein,Ruben A. Mesa +15 more
Journal ArticleDOI
Practical management of classical myeloproliferative disorder patients: a clinician's guide.
TL;DR: Management of the classical myeloproliferative disorders remains a significant challenge due to the varied range of prognosis and phenotypic manifestations, and elucidation of the role of the activating tyrosine kinase mutation JAK2 (V617F) is anticipated to usher in an era of greater understanding and targeted therapy for the MPDs.
Journal ArticleDOI
Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens
Prakash Thapaliya,Ayalew Tefferi,Animesh Pardanani,David P. Steensma,John K. Camoriano,Wenting Wu,Susan Geyer,Ruben A. Mesa +7 more
TL;DR: THAL-PRED based regimens are active in a subset of MF patients for therapy primarily of anemia, thrombocytopenia, and splenomegaly and for some patients a response of good duration (even after cessation of therapy) may be obtained.